Abstract
The phosphoinositide 3-kinase (PI3K) signaling cascade is a key mediator of cellular growth, survival and metabolism and is frequently subverted in human cancer. The gene encoding for the alpha catalytic subunit of PI3K (PIK3CA) is mutated and/or amplified in ∼30% of breast cancers. Mutations in either the kinase domain (H1047R) or the helical domain (E545K) are most common and result in a constitutively active enzyme with oncogenic capacity. PIK3CA H1047R was previously demonstrated to induce tumors in transgenic mouse models; however, it was not known whether overexpression of PIK3CA E545K is sufficient to induce mammary tumors and whether tumor initiation by these two types of mutants differs. Here, we demonstrate that expression of PIK3CA E545K in the mouse mammary gland induces heterogenous mammary carcinomas but with a longer latency than PIK3CA H1047R -expressing mice. Our results suggest that the helical domain mutant PIK3CA E545K is a less potent inducer of mammary tumors due to less efficient activation of downstream Akt signaling.
| Original language | English (US) |
|---|---|
| Article number | e74 |
| Journal | Oncogenesis |
| Volume | 2 |
| DOIs | |
| State | Published - Oct 18 2013 |
Fingerprint
ASJC Scopus subject areas
- Molecular Biology
- Cancer Research
Cite this
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. / Meyer, D. S.; Koren, S.; Leroy, C.; Brinkhaus, H.; Müller, U.; Klebba, I.; Müller, M.; Cardiff, Robert; Bentires-Alj, M.
In: Oncogenesis, Vol. 2, e74, 18.10.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
AU - Meyer, D. S.
AU - Koren, S.
AU - Leroy, C.
AU - Brinkhaus, H.
AU - Müller, U.
AU - Klebba, I.
AU - Müller, M.
AU - Cardiff, Robert
AU - Bentires-Alj, M.
PY - 2013/10/18
Y1 - 2013/10/18
N2 - The phosphoinositide 3-kinase (PI3K) signaling cascade is a key mediator of cellular growth, survival and metabolism and is frequently subverted in human cancer. The gene encoding for the alpha catalytic subunit of PI3K (PIK3CA) is mutated and/or amplified in ∼30% of breast cancers. Mutations in either the kinase domain (H1047R) or the helical domain (E545K) are most common and result in a constitutively active enzyme with oncogenic capacity. PIK3CA H1047R was previously demonstrated to induce tumors in transgenic mouse models; however, it was not known whether overexpression of PIK3CA E545K is sufficient to induce mammary tumors and whether tumor initiation by these two types of mutants differs. Here, we demonstrate that expression of PIK3CA E545K in the mouse mammary gland induces heterogenous mammary carcinomas but with a longer latency than PIK3CA H1047R -expressing mice. Our results suggest that the helical domain mutant PIK3CA E545K is a less potent inducer of mammary tumors due to less efficient activation of downstream Akt signaling.
AB - The phosphoinositide 3-kinase (PI3K) signaling cascade is a key mediator of cellular growth, survival and metabolism and is frequently subverted in human cancer. The gene encoding for the alpha catalytic subunit of PI3K (PIK3CA) is mutated and/or amplified in ∼30% of breast cancers. Mutations in either the kinase domain (H1047R) or the helical domain (E545K) are most common and result in a constitutively active enzyme with oncogenic capacity. PIK3CA H1047R was previously demonstrated to induce tumors in transgenic mouse models; however, it was not known whether overexpression of PIK3CA E545K is sufficient to induce mammary tumors and whether tumor initiation by these two types of mutants differs. Here, we demonstrate that expression of PIK3CA E545K in the mouse mammary gland induces heterogenous mammary carcinomas but with a longer latency than PIK3CA H1047R -expressing mice. Our results suggest that the helical domain mutant PIK3CA E545K is a less potent inducer of mammary tumors due to less efficient activation of downstream Akt signaling.
UR - http://www.scopus.com/inward/record.url?scp=84885435958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885435958&partnerID=8YFLogxK
U2 - 10.1038/oncsis.2013.38
DO - 10.1038/oncsis.2013.38
M3 - Article
C2 - 24080956
AN - SCOPUS:84885435958
VL - 2
JO - Oncogenesis
JF - Oncogenesis
SN - 2157-9024
M1 - e74
ER -